

Sorrento Therapeutics, Inc.  
Form 8-K  
October 15, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): October 14, 2014**

**SORRENTO THERAPEUTICS, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction of**  
**incorporation or organization)**

**001-36150**  
**(Commission**  
**File Number)**  
**6042 Cornerstone Ct. West, Suite B**

**33-0344842**  
**IRS Employer**  
**Identification No.)**

**San Diego, CA 92121**

Edgar Filing: Sorrento Therapeutics, Inc. - Form 8-K

**(Address of principal executive offices)**

**Registrant's telephone number, including area code: (858) 210-3700**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events.**

On October 14, 2014, Sorrento Therapeutics, Inc. (the Company) issued a press release announcing positive results from recently analyzed pharmacokinetic (PK) data from the first eight (8) patients enrolled in its ongoing TRIBECA (TRIAL establishing BE between Cynviloq and Albumin-bound paclitaxel) registrational trial. A copy of the press release is attached as Exhibit 99.1 and incorporated herein by reference.

The Company intends to conduct meetings with third parties in which its corporate slide presentation will be presented. The Company's presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

**(d) Exhibits.**

The following exhibit is filed with this Current Report on Form 8-K:

**Exhibit**

<b>No.</b>	<b>Description</b>
99.1	Press release of Sorrento Therapeutics, Inc., dated October 14, 2014
99.2	Corporate Presentation of Sorrento Therapeutics, Inc.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: October 14, 2014

SORRENTO THERAPEUTICS, INC.

By: /s/ Richard Vincent  
Name: Richard Vincent  
Title: Executive Vice President, Chief  
Financial Officer and Secretary